BGI Genomics Co. Ltd. Class A

BGI Genomics Co. Ltd. Class A

SSZSE:300676
35.37
CNY
-0.46
(-1.28%)
-1.35EPS
19.18BMarket Cap
Apr 26Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
12.8
4.43
3.87
4.73
5.53
6.34
7
21.1
16.5
17.19
10.61
9.38
8.9
8.94
Basic EPS, GAAP
1.66
0.11
0.77
0.92
1.05
0.97
0.69
5.25
3.56
1.96
0.23
-2.19
-1.48
-1.31
Free Cash Flow per Basic Share
-3.03
-2.21
0.44
-0.03
-0.13
-1.66
-1.01
8.3
5.1
-2.77
-2.02
-1.05
-1.37
- -
Dividend per Share
- -
- -
- -
0.23
0.29
0.5
0.1
0.16
0.43
0.41
1.02
0.12
0.04
0.04
Book Value per Share
1.11
3.29
8.6
9.33
10.37
10.13
10.91
14.77
22.51
24.34
23.82
21.97
20.31
19.7
Tangible Book Value per Share
0.52
2.73
8.07
8.86
9.97
9.61
10.35
14.21
21.62
22.95
22.3
20.66
19.1
18.58
Basic Weighted Avg Shares
82
256
340
362
379
400
400
398
410
410
410
412
416
417
Sales/Revenue/Turnover
1,047
1,132
1,319
1,711
2,096
2,536
2,800
8,397
6,766
7,053
4,350
3,867
3,705
3,725
Operating Margin (%)
20.88
5.51
20.12
19.12
23.17
19.43
14.42
33.5
27.31
17.75
5.32
-10.58
-4.59
-2.29
Depreciation Expense
41
91
89
95
113
169
241
302
371
453
437
484
518
- -
Net Income, GAAP
136
28
262
333
398
387
276
2,090
1,462
803
93
-903
-617
-545
Effective Tax Rate (%)
15.63
21.87
16.08
14.56
14.6
14.12
15.13
13.93
15.36
19.62
18.92
- -
- -
- -
Profit Margin (%)
12.97
2.48
19.88
19.44
19
15.24
9.87
24.89
21.6
11.38
2.14
-23.34
-16.64
-14.63
Working Capital
31
683
2,360
2,471
3,019
2,141
2,123
4,570
7,651
5,819
4,636
4,034
3,613
3,657
LT Debt
- -
2
- -
- -
- -
- -
301
802
716
137
283
389
516
641
Total Equity
598
1,466
3,169
3,453
4,258
4,132
4,458
6,026
9,441
10,221
10,004
9,272
8,608
8,349
Return on Invested Capital (%)
42.26
3.95
10.93
9.84
11.26
9.97
6.65
37
18.02
8.57
1.17
- -
- -
- -
Return on Capital (%)
30.27
-0.2
10.87
9.49
9.6
8.64
6.21
34.96
17.21
8.17
1.49
- -
- -
- -
Return on Common Equity (%)
52.96
3.55
12.24
10.31
10.6
9.43
6.57
40.68
19.19
8.28
0.93
-9.5
-7
-6.23

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
122
84
80
LT Borrowings
417
417
613
LT Finance Leases
64
32
27
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
418
418
418
Market Capitalization
16,670
14,666
19,184

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,813
5,687
5,655
Cash, Cash Equivalents & STI
3,365
3,163
3,162
Accounts Receivable, Net
1,710
1,821
1,748
Inventories
466
498
538
Total Current Liabilities
2,239
2,022
1,998
Payables & Accruals
- -
- -
- -
ST Debt
122
84
80
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.07%
9.67%
-7.16%
Free Cash Flow
28.87%
-46.88%
31.21%
Net Income, GAAP
-59.53%
-253.39%
-31.69%
Sales/Revenue/Turnover
21.48%
-13.76%
-4.18%
Total Cash Common Dividend
1,093.19%
35.04%
-65.68%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
821
1,050
954
1,041
3,867
2025
672
960
- -
1,032
3,705
2026
809
980
904
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.01
-0.35
-1.89
-2.19
2025
-0.13
0.14
- -
-1.43
-1.48
2026
-0.02
0.14
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.11
0.01
0.12
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Yong Hou
Full Time Employees
3,580
Sector
Health technology
Industry
Biotechnology
Address
BGI Center Shenzhen GD China 518081
IPO Date
Jul 14, 2017
Website
bgi.com
Business
BGI Genomics Co., Ltd. (300676.SZ) provides genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers, and other organizations in China and internationally; offers DNA, RNA, customized sequencing solutions, and mass spectrometry services; delivers solutions for basic research in human, plant, animal, and microbial species, clinical research in human health, genetic testing and screening, drug discovery and development, agriculture, and biodiversity preservation; provides diagnostics and precision medicines for COVID-19, infectious diseases, and oncology, including COVID-19 PCR test kits and lab solutions; supplies reproductive health basic research and clinical application services, cancer and chronic disease prevention and translational medicine services, infection prevention and control services, multi-omics big data services, and comprehensive precision medical testing solutions. BGI Genomics operates as a subsidiary of BGI Group, founded in 1999 and headquartered in Shenzhen, China, with geographic operations spanning over 100 countries including Europe, North America, Asia-Pacific, and emerging markets in Asia and Africa. The company launched a new line of next-generation sequencing products in 2023, acquired a biotechnology firm specializing in AI-driven diagnostics in January 2023, formed strategic partnerships with pharmaceutical companies for drug discovery integration, and continues international expansion with new branches and multi-omics sequencing centers.